Eli Lilly and Company (NYSE:LLY) Trading Down 1.3% – Should You Sell?

Eli Lilly and Company (NYSE:LLY) shares traded down 1.3% during mid-day trading on Wednesday . The company traded as low as $1,022.32 and last traded at $1,033.0030. 3,381,716 shares were traded during trading, a decline of 17% from the average session volume of 4,052,825 shares. The stock had previously closed at $1,046.12.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Weiss Ratings upgraded Eli Lilly and Company from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. HSBC raised their price objective on shares of Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. UBS Group upped their target price on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a “buy” rating in a research note on Friday, November 7th. National Bankshares set a $1,286.00 price target on shares of Eli Lilly and Company in a research report on Monday. Finally, JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,087.32.

Eli Lilly and Company Price Performance

The company has a market capitalization of $954.13 billion, a P/E ratio of 49.38, a PEG ratio of 1.13 and a beta of 0.37. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The business has a 50 day simple moving average of $918.84 and a 200-day simple moving average of $809.30.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company’s quarterly revenue was up 53.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s payout ratio is 29.35%.

Hedge Funds Weigh In On Eli Lilly and Company

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Lazard Freres Gestion S.A.S. lifted its holdings in shares of Eli Lilly and Company by 114.3% in the second quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock worth $60,253,000 after buying an additional 41,222 shares in the last quarter. Precedent Wealth Partners LLC increased its holdings in Eli Lilly and Company by 15.3% during the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after acquiring an additional 39 shares during the period. Capital Advisors Inc. OK increased its holdings in Eli Lilly and Company by 6.8% during the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock worth $5,260,000 after acquiring an additional 429 shares during the period. Family CFO Inc purchased a new stake in Eli Lilly and Company in the 2nd quarter worth approximately $54,000. Finally, Duquesne Family Office LLC boosted its holdings in Eli Lilly and Company by 52.5% in the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after purchasing an additional 32,640 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.